CW Group is looking to raise $100 million for CW Ventures III, which will invest in early-stage health care companies. As much as half of the money could go to biotechnology, "if you include the information-technology investments," said Lawrence Bock, who joined CW Group as general partner in the firm's new San Diego office. Bock was formerly general partner at Avalon Ventures.

"A major area of interest is technology for accelerating the drug development